Every supplement on the nitric oxide market today shares the same assumption: give the body a precursor and let NOS do the rest. L-arginine, L-citrulline, beetroot nitrate — they all feed into enzymatic pathways that the body is already struggling to run efficiently. My research takes a fundamentally different position.
The standard model works like this: you consume a precursor, the enzyme converts it, and nitric oxide is produced. Simple in theory. In practice, the enzyme — NOS — becomes progressively less efficient with age, oxidative stress, and metabolic disruption. By the time most people begin supplementing, the very machinery they are relying on has already declined.
My fermented metabolite delivers bioavailable nitric oxide without routing through any of these enzymatic steps. The fermentation process itself produces the active molecule — meaning the body receives it directly rather than having to manufacture it from a precursor. The practical result is consistency: the benefit does not quietly erode as enzymatic efficiency drops with age.
“We spent two decades asking a single question: what if the body did not need to make the nitric oxide at all? The metabolite is the answer to that question.”
The supplement market will catch up to this eventually. Until then, the distinction between precursor-based and metabolite-based delivery is the most important one a consumer can understand.